David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the findings from the single-arm AZUR-1 (NCT05723562) trial evaluating anti-PD-1 dostarlimab in patients with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer (LARC), with a primary endpoint of clinical complete response maintained at least for 12 months. The results show a 26% complete response rate, which increases to 76% when including patients with surgical and pathological complete response. Dr Tougeron emphasizes the potential for immunotherapy and non-operative management to become a new standard of care for MSI patients, avoiding the need for chemotherapy, radiation, and surgery. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.